Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer

Abstract

Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.

Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time

“…Laboratory Investigation (2015) 95, 334-341; doi:10.1038/labinvest.2014.139; published online 24 November 2014 Recently, efforts have been made to improve individualized targeted therapy for cancer patients according to the expression of specific genes and proteins [1][2][3][4] and according to their status of activation as characterized by phosphorylation of specific epitopes. Phosphorylation of proteins is one of the most important modulatory mechanisms of activation of a number of molecular pathways and a potential indicator of cellular proliferation, migration, and other cellular functions.…”

Cancer Chemoprevention

“…However, other cancer biomarkers have proven controversial due to their low specificity. 5 This is the case with the serum prostate-specific antigen (PSA) that, despite its low specifity, has guided prostate cancer diagnosis and management. New prostate cancer biomarkers that may supplement or replace PSA are emerging in large part from new genomic technologies, but this research has centered on disease diagnostics rather than on prognosis and prediction.…”

DGIdb 2.0: mining clinically relevant drug–gene interactions

“…With the increasing availability and decreasing cost of molecular profiling methods, growing attention has been paid to the use of these technologies for characterizing the mechanisms of human disease at the cohort—and more recently, the individual—level ( 1 – 3 ). Improved understanding of such molecular characteristics has been demonstrated to impact the diagnostic, prognostic, and treatment decisions made by clinicians, yielding positive results, less toxicity and improved quality of life ( 4 , 5 ). However, finding well-annotated drug–gene interactions relevant to medical decision-making remains an ongoing challenge.…”